Corbevax likely to be available at vaccination centres from tomorrow

The recently approved heterologous Covid19 vaccine Corbevax is expected to be available as a booster dose on the COWIN App in both public and private vaccination centres from Friday manufacturer Biological E Limited BE saidCorbevax was approved as Indias First Heterologous Covid19 booster shot for 18 Years and above after the six months of administration of the primary vaccination doses of Covaxin or Covishield People who have taken Covaxin or Covishield can be administrated a Corbevax booster shot in emergency use authorisationThe Union Health Ministry approved Corbevax for emergency use on the basis of a recently made recommendation by the Covid19 Working Group of the National Technical Advisory Group on Immunisation NTAGIThis approval came after the Drug Controller General of India DCGI approved the vaccine for emergency use as a heterologous Covid19 booster dose for individuals aged 18 years on June 4 2022 an official statement from the BE saidIt further added that the Corbevax had received emergency use authorization as a primary twodose vaccination regimen in Adults Adolescents and Children aged 5 years and above in a series of approvals from December21 to April22Also Read Maharashtra reports 1877 new Covid19 cases 5 deathsThe Hyderabadbased pharmaceutical company BE has so far delivered 10 crore doses of Corbevax to the CentrePanIndia rollout of the booster shot vaccine in children aged between 12 to 14 years was initiated on March 16 2022 and till now almost 7 crore doses have been administered and 29 crore children completed their twodose vaccination regimen it saidAccording to the manufacturer company the vaccine has undergone comprehensive booster trials on Indian subjects and subsequently received approval from the Indian regulatory authorityBEs Corbevax is the first Indian vaccine to be approved as a heterologous Covid19 booster dose It uses a traditional recombinant proteinbased technology which is also used for vaccines such as Hepatitis BThe Corbevax heterologous boosterdose clinical trials demonstrated a significant boosting of humoral immune response measured in terms of neutralization antibody titres against the ancestral as well as the omicron strain binding antibody titres as well as cellular immune response along with minimal adverse events that were mild in natureCorbevax has become the first vaccine in India to be approved as a heterologous Covid19 booster The approval by the Ministry of Health today is another important step in combating the pandemic We are very pleased with this endorsement which recognizes the safety and efficacy of our vaccine said Mahima Datla Managing Director Biological E LimitedThe price of Corbevax for private Covid19 vaccination centres is Rs 250 inclusive of the Goods and Sales taxFor the enduser the price of the vaccine is Rs 400 including taxes and administrative charges Corbevax is expected to be available as a booster dose on the CoWIN App in public and private vaccination centres from August 12 2022This story has been sourced from a third party syndicated feed agencies Midday accepts no responsibility or liability for its dependability trustworthiness reliability and data of the text Midday managementmiddaycom reserves the sole right to alter delete or remove without notice the content in its absolute discretion for any reason whatsoever